SinoMab BioScience EPS
¿Qué es el EPS de SinoMab BioScience?
El EPS de SinoMab BioScience Limited es -0.16
¿Cuál es la definición de EPS?
Las ganancias por acción (EPS) son la parte de las ganancias de una empresa asignada a cada acción en circulación de acciones ordinarias. Se ajusta para la dilución y se calcula a lo largo de doce meses.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS de compañías en Sector Health Care en HKSE en comparadas con SinoMab BioScience
¿Qué hace SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Empresas con eps similar a SinoMab BioScience
- Taizhou Water Co tiene EPS de -0.16
- Jiangsu Jingyuan Environmental Protection Co tiene EPS de -0.16
- Venus Medtech (Hangzhou) Inc tiene EPS de -0.16
- Hive Blockchain Technologies tiene EPS de -0.16
- Honworld tiene EPS de -0.16
- TUS International tiene EPS de -0.16
- SinoMab BioScience tiene EPS de -0.16
- Emerita Resources tiene EPS de -0.16
- Tiziana Life Sciences Plc tiene EPS de -0.16
- Interbit tiene EPS de -0.16
- Accuray tiene EPS de -0.15
- Mercator tiene EPS de -0.15
- Century City International tiene EPS de -0.15